[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1488
1. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K: Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer; 2006 Nov 15;107(10):2468-73
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma.
  • BACKGROUND: [(18)F]Fluoro-2-deoxyglucose uptake on positron emission tomography (FDG-PET) has been frequently used for diagnosis and staging of lung cancer.
  • The prognostic significance of FDG uptake on PET was evaluated in patients with pathologic Stage I lung adenocarcinoma (tumor stages were based on the TNM classification of the International Union Against Cancer).
  • METHODS: Disease-free survival of 98 patients with pathologic Stage I lung adenocarcinoma who were treated by curative resection was examined in relation to sex, age, histologic grade of differentiation, surgical procedure, tumor stage, and FDG uptake measured as the maximum standardized uptake value (SUV).
  • RESULTS: Sixty-three patients were had Stage IA disease and 35 patients had Stage IB disease.
  • Six patients each with Stage IA and Stage IB disease developed disease recurrence after a mean postsurgical follow-up period of 31 months.
  • Ten (20%) of the 51 patients with moderately or poorly differentiated adenocarcinoma developed disease recurrence, compared with 2 (4%) of the 47 patients with well-differentiated adenocarcinoma (P = .056).
  • CONCLUSIONS: FDG uptake appears to be predictive of disease-free survival in patients with Stage I lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036361.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, Oka T, Gong Y, Guo R, Inada H, Nawa K, Kojika M, Suga Y, Ohira T, Mukai K, Kato H: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer; 2008 Feb 12;98(3):596-603
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
  • Although postoperative adjuvant chemotherapy (PAC) with uracil-tegafur significantly improves the prognosis of patients with stage I lung adenocarcinoma, subset analysis has revealed that only 11.5% of patients with stage IB derive actual benefit from such therapy.
  • We performed comprehensive protein analysis of 24 surgically resected specimens of stage I adenocarcinoma using liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by bioinformatical investigations to identify protein molecules.
  • Furthermore, we carried out immunohistochemical studies of 90 adenocarcinoma specimens to validate the results of LC-MS/MS.
  • Cases of adenocarcinoma lacking expression of either myosin IIA or vimentin show a good outcome without PAC, and therefore do not require such treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Lung Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 May 18;105(4):425-31 [11371340.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61 [14519751.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):999-1012 [15195114.001]
  • [Cites] J Pathol. 1996 Oct;180(2):175-80 [8976877.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 1):1643-54 [8978829.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):483-95 [9033265.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2085-8 [9748123.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Proteomics. 2005 Mar;5(4):856-64 [15668996.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Tumour Biol. 2005 May-Jun;26(3):153-7 [15970650.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):677-80 [16243835.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Gan. 1979 Apr;70(2):209-14 [381088.001]
  • [Cites] Gan. 1979 Jun;70(3):353-9 [467897.001]
  • [Cites] Oncogene. 1993 Apr;8(4):999-1008 [8455951.001]
  • [Cites] Am J Clin Pathol. 1994 Aug;102(2):171-5 [8042584.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • (PMID = 18212748.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vimentin; 1548R74NSZ / Tegafur; EC 3.6.1.- / Nonmuscle Myosin Type IIA
  • [Other-IDs] NLM/ PMC2243141
  •  go-up   go-down


3. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL: Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol; 2010 Aug;34(8):1193-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.
  • Many patients with stage I nonsmall cell lung carcinoma will develop recurrence after surgical excision.
  • Sox2 is a marker of embryonic stem cell pluripotency that is associated with aggressive tumor behavior and is expressed in a subset of lung adenocarcinomas.
  • We hypothesized that Sox2 expression may provide prognostic information in early stage lung adenocarcinomas.
  • We evaluated formalin-fixed, paraffin-embedded tissue from 104 stage I lung adenocarcinomas resected between 1997 and 2000.
  • Sox2 expression was detected in 50% of the cases and was more frequent in tumors from older and male patients but not significantly associated with smoking status, tumor stage, grade, or histologic subtype.
  • Sox2 seems to be an independent predictor of poor outcome in stage I lung adenocarcinomas and may help stratify patients at increased risk for recurrence.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2006 Dec;3(12):e467 [17194181.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):364-8 [17093407.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5562-9 [18065728.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] J Neurosci Res. 2008 Jun;86(8):1680-93 [18293417.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2846-53 [18539963.001]
  • [Cites] J Biol Chem. 2008 Jun 27;283(26):17969-78 [18456656.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94 [19033571.001]
  • [Cites] Methods Mol Biol. 2009;472:397-411 [19107445.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2824-8 [19196983.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1091-9 [19188679.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2660-7 [19414679.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6386-90 [19808871.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1238-42 [19801978.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):55-61 [19661786.001]
  • [Cites] Am J Pathol. 2010 Feb;176(2):903-13 [20042675.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):1977-86 [19040416.001]
  • [Cites] Semin Surg Oncol. 2003;21(2):74-84 [14508857.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):79-82 [9591638.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2468-77 [9667266.001]
  • [Cites] Dev Dyn. 1998 Dec;213(4):464-75 [9853967.001]
  • [Cites] Ann Thorac Surg. 2006 Jun;81(6):1958-62; discussion 1962 [16731113.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):790-800 [16873561.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):533-8 [16767105.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • (PMID = 20631605.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090578-060010; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / 2P50 CA090578-06; United States / NCI NIH HHS / CA / P50 CA090578-060010
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  • [Other-IDs] NLM/ NIHMS221695; NLM/ PMC2923819
  •  go-up   go-down


Advertisement
4. Okudela K, Woo T, Mitsui H, Yazawa T, Shimoyamada H, Tajiri M, Ogawa N, Masuda M, Kitamura H: Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease. Int J Clin Exp Pathol; 2010;3(4):348-66
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease.
  • We have established a concise sub-typing system suitable for predicting the postoperative outcome in cases of stage I lung adenocarcinoma (ADC), using morphometric profiling.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1071-8 [15195116.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Am J Surg Pathol. 2010 Feb;34(2):243-55 [20061937.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):370-4 [9708203.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] Lung Cancer. 2007 Jun;56(3):341-8 [17350137.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1532-41 [17702091.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):46-52 [18166840.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):355-62 [19162366.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 20490327.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2872743
  • [Keywords] NOTNLM ; Lung adenocarcinoma / altered sub-typing system / morphometric profiling / prognostic value / stage I
  •  go-up   go-down


5. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, Buttitta F, Felicioni L, Nicassio F, Di Fiore PP: Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest; 2007 Nov;117(11):3436-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.
  • Adenocarcinoma is the predominant histological subtype of lung cancer, the leading cause of cancer deaths in the world.
  • At stage I, the tumor is cured by surgery alone in about 60% of cases.
  • To achieve this goal, we used an integrated strategy combining meta-analysis of published lung cancer microarray data with expression profiling from an experimental model.
  • The resulting 80-gene model was tested on an independent cohort of patients using RT-PCR, resulting in a 10-gene predictive model that exhibited a prognostic accuracy of approximately 75% in stage I lung adenocarcinoma when tested on 2 additional independent cohorts.
  • [MeSH-major] Adenocarcinoma. Gene Expression Regulation, Neoplastic. Lung Neoplasms. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Apr;158(4):1451-63 [11290563.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3244-50 [12036940.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Lung Cancer. 2005 Dec;50 Suppl 2:S9-16 [16557669.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1679-88 [16549822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5923-8 [16585533.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Aug;5(5):365-80 [16101384.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):3015-25 [16224537.001]
  • [Cites] Lung Cancer. 2005 Oct;50 Suppl 1:S2-4 [16291427.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Lung Cancer. 2006 Nov;54(2):227-34 [16935391.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):293-301 [17011066.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7279-83 [17189399.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e467 [17194181.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] BMC Bioinformatics. 2006;7 Suppl 4:S8 [17217526.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3005-8 [12036904.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2883-9 [12231532.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):226-30 [12754511.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3548-53 [12789263.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 10):19-25 [12917817.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1318-25 [14977831.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1338-43 [14977834.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1539-48 [14661056.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):811-9 [14990636.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1157-61; discussion 1161-2 [15063225.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1555-62 [15083185.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] BMC Bioinformatics. 2004 Jun 24;5:81 [15217521.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1328-33 [7882331.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Ann Thorac Surg. 1999 Apr;67(4):927-32 [10320230.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Apr;15(4):438-43 [10371118.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4204-7 [10485455.001]
  • [Cites] EMBO J. 2004 Dec 8;23(24):4709-16 [15538380.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Lung Cancer. 2005 Feb;47(2):183-92 [15639717.001]
  • [Cites] Lung Cancer. 2004 Dec;46 Suppl 2:S33-9 [15698530.001]
  • [Cites] Lancet Oncol. 2005 Mar;6(3):182-4 [15759364.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3198-204 [15867213.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):159-70 [15892617.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):476-86 [15928711.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):3974-86 [15930332.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):3017-24 [15840707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7 [11416219.001]
  • (PMID = 17948124.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2030461
  •  go-up   go-down


6. Kashiwabara K, Saeki S, Sasaki J, Nomura M, Kohrogi H: Combined evaluation of postoperative serum levels of carcinoembryonic antigen less than or equal to 2.5 ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer. J Thorac Oncol; 2008 Dec;3(12):1416-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined evaluation of postoperative serum levels of carcinoembryonic antigen less than or equal to 2.5 ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer.
  • STUDY OBJECTIVES: It has been reported that high levels of serum carcinoembryonic antigen (CEA) after surgery, or the presence of vascular invasion or both, are strong indicators of postoperative recurrence in patients with non-small cell lung cancer.
  • The purpose of this study is to evaluate which kind of patients with p-stage I adenocarcinoma need adjuvant chemotherapy, using those predictors.
  • PATIENTS AND METHODS: We studied 136 patients with curatively resected p-stage I adenocarcinoma during the 7-year period of January 1, 2000 to December 31, 2006.
  • Fifteen (11%) of 136 patients had postoperative recurrence (7 p-stage IA cases and 8 p-stage IB cases).
  • CONCLUSION: Combined evaluation of postoperative CEA levels and vascular invasion makes it possible to predict disease recurrence in the curatively resected p-stage I adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoembryonic Antigen / blood. Lung Neoplasms / blood. Neoplasm Recurrence, Local / diagnosis. Neovascularization, Pathologic / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057266.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


7. Shu Y, Iijima T, Sun W, Kano J, Ishiyama T, Okubo C, Anami Y, Tanaka R, Fukai S, Noguchi M: The ACIN1 gene is hypermethylated in early stage lung adenocarcinoma. J Thorac Oncol; 2006 Feb;1(2):160-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ACIN1 gene is hypermethylated in early stage lung adenocarcinoma.
  • We hypothesized that characteristic aberrant hypermethylation of CpG islands of certain genes may exist in the early stages of lung adenocarcinoma and that such alterations may be useful in the detection and treatment of early lung adenocarcinoma.
  • A higher frequency of hypermethylation at a locus at the 5': end of the DNA fragment isolated from the ACIN1 gene was found in small-sized adenocarcinoma (2 cm or less) (30/37, 81%) compared with normal lung tissue (9/37, 24%, p < 0.05).
  • Interestingly, hypermethylation of ACIN1 was detected relatively frequently in the normal counterpart of adenocarcinoma without bronchioloalveolar carcinoma (BAC) component (7/16, 44%), but was rare in the normal counterpart of adenocarcinoma with BAC component (2/21, 10%, P < 0.05).
  • CONCLUSIONS: We found hypermethylation of the ACIN1 gene in early stage lung adenocarcinoma.
  • The role of methylation status in the development and malignant transformation of lung adenocarcinoma requires clarification.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Lung Neoplasms / genetics. Nuclear Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409846.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACIN1 protein, human; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Nuclear Proteins
  •  go-up   go-down


8. Murthy SC, Reznik SI, Ogwudu UC, Farver CF, Arrossi A, Batizy LH, Nowicki ER, Mekhail TM, Mason DP, Rice TW, Blackstone EH: Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung. Ann Thorac Surg; 2010 Oct;90(4):1067-74
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung.
  • BACKGROUND: Understanding recurrence of surgically "cured" stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease.
  • METHODS: From 1991 to 2001, 285 patients underwent resection of stage I adenocarcinoma (pathologic) of the lung.
  • CONCLUSIONS: Stage I adenocarcinoma of the lung recurs.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20868788.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Duan Y, Bai LQ: [Long-term results of surgical plus chemotherapy for stage I lung adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Jun 16;89(23):1630-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of surgical plus chemotherapy for stage I lung adenocarcinoma].
  • OBJECTIVE: Observe the effect of operation plus post-operative chemotherapy for long-term results of stage I lung adenocarcinoma.
  • METHODS: From January 1994 to January 2005, 427 patients with stage I lung adenocarcinoma underwent surgical resection therapy.
  • The comparison of long-term survival rates was made between post-chemotherapy and surgical resection alone.
  • RESULTS: The analyses disclosed that the stage I a 1, 3, 5 and 10-year survival rate of post-chemotherapy was 100.00%, 92.34%, 86.17% and 74.82%, respectively, while in surgical resection alone was 96.63%, 88.11%, 79.52% and 65.85%, respectively.
  • The stage I b 1, 3, 5 and 10-year survival rate of post-chemotherapy was 96.84%, 77.99%, 69.56% and 64.36%, respectively, while in surgical resection alone was 85.65%, 67.11%, 59.56% and 53.06%, respectively.
  • There was statistically significant difference between 1 year survival rate of stage I a patients with post-chemotherapy and those with surgical resection alone (P < 0.05); 1 year survival rate of stage I b patients with post-chemotherapy and those with surgical resection alone (P < 0.01).
  • CONCLUSION: The operation plus post-operative chemotherapy is better than surgical resection alone in stage I a and I b.
  • Surgical plus post-operative chemotherapy mode is indispensable for better prognosis of stage I a and I b lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957512.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Ohta S, Hirose M, Ishibashi H, Muro H: [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?]. Kyobu Geka; 2007 Jul;60(7):519-22; discussion 522-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?].
  • OBJECTIVE: This study was done for the purpose of picking out the cases of poor prognosis from the peripherally located stage I adenocarcinoma of the lung.
  • METHODS: Between January 1989 and December 2004, 235 patients with peripherally located stage I adenocarcinoma of the lung were resected curatively in our hospital.
  • The ratio of the cases without ductal invasion was 61% in stage IA, and 31% in stage IB.
  • The 5-year survival rate was 99% in the cases without ductal invasion in stage IA, 100% in the cases without ductal invasion in stage IB, 90% in the cases with ductal invasion in stage IA, and 65% in the cases with ductal invasion in stage IB, respectively.
  • And the 5-year survival rate without recurrence was 94% in the cases without ductal invasion in stage IA, 76% in the cases without ductal invasion in stage IB, 76% in the cases with ductal invasion in stage IA, and 54% in the cases with ductal invasion in stage IB, respectively.
  • CONCLUSIONS: Ductal invasion is significant prognostic factor in stage I adenocarcinoma of the lung.
  • Adjuvant chemotherapy is unnecessary for the case without ductal invasion in stage IA.
  • But we think that adjuvant chemotherapy is necessary for the case with ductal invasion in stage IA and for the case in stage IB, because there is much recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642210.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Cho S, Sung SW, Jheon S, Chung JH: Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis. Lung; 2008 Nov-Dec;186(6):411-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis.
  • STUDY OBJECTIVES: Stage I adenocarcinoma of the lung is the most common type of lung cancer.
  • A better understanding of the histopathology and molecular biology of lung cancer might improve the capability to predict the outcome for any individual patient.
  • The purpose of this study was to evaluate several histopathologic and molecular markers in order to assess their prognostic value in stage I adenocarcinoma.
  • CONCLUSIONS: In resected stage I adenocarcinoma, necrosis, lymphatic vessel invasion, E-cadherin, and p53 have been identified as independent predictors of disease-free survival.
  • [MeSH-major] Adenocarcinoma / pathology. Cadherins / analysis. Ki-67 Antigen / analysis. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836777.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


12. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL: Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol; 2009 Jan 10;27(2):271-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.
  • PURPOSE: Thyroid transcription factor 1 (TTF1) is a transcription factor that regulates the expression of multiple genes involved in lung development.
  • It is preferentially expressed in adenocarcinomas of the lung and has been investigated as a potential prognostic parameter in patients with lung cancer, with conflicting results.
  • TTF1 was consistently expressed in adenocarcinomas (n = 61 and 73; Spearman rho = 0.313 and 0.4 for the first and second set, respectively; P < .0001) independent of their differentiation and stage.
  • Survival analysis showed that patients with stage I adenocarcinoma with TTF1 expression had a longer median overall survival than those without expression (n = 43, 44.3 v 26.2 months, P = .05 for the first cohort; n = 87; 49.7 v 38.5 months, P = .03 for the second cohort) Multivariate analysis revealed an independent lower risk of death for patients with stage I adenocarcinoma with TTF1-expressing tumors (hazard ratio = 0.479, 95% CI, 0.235 to 0.977; P = .043).
  • CONCLUSION: TTF1 expression defines a subgroup of patients with a favorable outcome and may be useful for prognostic stratification of patients with stage I lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Lung Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


13. Mizuno T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mochizuki T, Kawai O, Hasebe T, Ochiai A: Identification of a low risk subgroup of stage IB lung adenocarcinoma patients. Lung Cancer; 2008 Dec;62(3):302-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a low risk subgroup of stage IB lung adenocarcinoma patients.
  • OBJECTIVES: Several trials have recently reported the efficacy of adjuvant chemotherapy for resected stage IB non-small cell lung cancer (NSCLC).
  • However, the histological findings and prognosis of stage IB lung adenocarcinoma vary considerably.
  • The aim of this study was to investigate prognostic factors of resected stage IB adenocarcinoma and identify a subgroup with a better prognosis, in which adjuvant chemotherapy could be omitted.
  • METHODS: We reviewed 413 cases of stage I lung adenocarcinoma treated by surgical resection, and investigated prognostic factors that favorably affected the survival of 106 patients with stage IB lung adenocarcinoma.
  • A subgroup with a better outcome was identified and their survival was compared with that of stage IA patients.
  • RESULTS: The 5-year survival rate of the stage IB adenocarcinoma patients was 81.7%.
  • The 5-year survival rate of the stage IB adenocarcinoma patients without pleural invasion (76 cases) was 89.3%, and it was not statistically different from that of the stage IA patients (92.7%).
  • CONCLUSIONS: The stage IB lung adenocarcinoma patients without pleural invasion had a favorable outcome that was almost the same as that of stage IA patients.
  • Because adverse effects of chemotherapy are sometimes severe and unacceptable, adjuvant chemotherapy can be omitted for stage IB adenocarcinoma without pleural invasion.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486987.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


14. Girvan AC, Peltz G, Pennella E, Pohl G, Faries D, Marciniak MD, Obasaju CK, Stepanski EJ, Schwartzberg LS, Adjei AA: An observational study of the impact of ethnicity on patients treated for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed: Preliminary results in African Americans. J Clin Oncol; 2009 May 20;27(15_suppl):e20624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An observational study of the impact of ethnicity on patients treated for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed: Preliminary results in African Americans.
  • : e20624 Background: African-Americans are more likely to develop and die from lung cancer than persons of any other ethnic group.
  • This prospective, single-arm, observational study evaluates the impact of ethnicity on disease control rate (DCR) (CR + PR + SD)) in patients (pts) with non-small lung cancer (NSCLC) being treated with pemetrexed (Pem) in the second-line setting.
  • METHODS: Eligibility criteria include stage IIIB or IV NSCLC pts receiving Pem for second-line therapy with no restrictions on performance status.
  • Demographics of Caucasians: M/F (136:107); median age 66 (range 37-88); histology adenocarcinoma/squamous/other/unknown (141:67:33:2).
  • Demographics of African-Americans: M/F (21:13); median age 64 (range 43-80); histology adenocarcinoma/squamous/other/unknown (22:9:3:0).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Janjigian YY, Park BJ, Kris MG, Miller VA, Riely GJ, Zheng J, Dycoco JP, Shen R, Azzoli CG: Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations. J Clin Oncol; 2009 May 20;27(15_suppl):7523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations.
  • : 7523 Background: Patients with stage IV adenocarcinoma whose tumors harbor EGFR mutations have high rates of response (∼ 75%) and prolonged progression free survival after EGFR tyrosine kinase inhibitor (TKI) treatment.
  • To see if adjuvant treatment with EGFR TKI (gefitinib or erlotinib) improves DFS in patients with EGFR mutation NSCLC, we conducted a retrospective review of patients with resected lung adenocarcinoma harboring EGFR mutations, some of whom received EGFR TKIs postoperatively.
  • METHODS: With Institutional Review Board approval, clinical information was obtained on all patients with stage I-III lung adenocarcinoma harboring EGFR exon 19 or 21 mutations that underwent resection at MSKCC between May 2002 and August 2008.
  • Age, gender, type of surgery, histology, EGFR mutation status (exon 19 deletions and exon 21 L858R), stage, perioperative therapy and survival were recorded.
  • RESULTS: We studied 150 patients (112 women, 38 men) with completely resected stage I-III lung adenocarcinoma whose resection specimens contained EGFR activating mutations in exon 19 or 21.
  • After controlling for stage, individuals who received adjuvant gefitinib or erlotinib had a better DFS (HR=0.38, 95%CI: 0.16-0.90) than the non-TKI group (p=0.03).
  • CONCLUSIONS: These data indicate that the adjuvant use of either gefitinib or erlotinib improves DFS in patients with completely resected stage I -III lung adenocarcinomas with mutations in EGFR exons 19 and 21.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963290.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Vinolas N, Magem M, Garrido P, Artal A, De Castro J, Campelo RG, Isla D, Felip E, Amador M, Rosell R: Lung cancer in women: The Spanish female-specific database WORLD 07. J Clin Oncol; 2009 May 20;27(15_suppl):8084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in women: The Spanish female-specific database WORLD 07.
  • : 8084 Background: Lung cancer is the leading cause of cancer mortality among women in many countries.
  • METHODS: WORLD07 is a prospective, multicenter, epidemiologic female-specific lung cancer database developed by the Spanish Lung Cancer Group.
  • Data on demographics, previous cancer history, reproductive and hormonal status, diet, alcohol, tobacco, and occupational information are being collected just as histology, stage, treatment and survival.
  • RESULTS: From October 2007 to Nov 2008, 342 female newly diagnosed of lung cancer were collected in an e-database in 20 Spanish centers.
  • Familial history of cancer: 45.5% (lung cancer 29.7%).
  • Current lung cancer histology (%): adenocarcinoma/BAC/squamous/large cell/NOS: 70.4/5.7/10.4/7.9/5.7.
  • Available data of 122 stage IV NSCLC p: 74.6% receive chemotherapy, 92.3% of them two drugs and 68.9 % platinum-based (59% cisplatin).
  • CONCLUSIONS: According this series, 42% of Spanish lung cancer women are never smokers and 70.4% have adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962661.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • It is unclear whether these phenotypic similarities between normal/embryonic stem cells and mature tumor cells, specific to lung cancer, are a result of underlying biologic processes, such as specific molecular pathways and regulatory networks.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).
  • CONCLUSIONS: Lung adenocarcinomas that share a common gene expression pattern with normal stem cells were associated with decreased survival and increased likelihood of resistance to cisplatin, indicating the aggressiveness of lung tumors with a stem cell phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kayali F, Janjua MA, Laber DA, Miller DM, Day JM, Kloecker GH: Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC).
  • All patients had unresectable stage III/IV at diagnosis.
  • Histologies were 50% adenocarcinoma, 30% squamous and 20% unspecified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962216.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Strickler JH, Mostertz W, Kim W, Walters K, Stevenson M, Acharya C, Onaitis M, Nevins J, Potti A: Integration of mRNA and microRNA profiles as prognostic and predictive markers in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):7522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of mRNA and microRNA profiles as prognostic and predictive markers in lung adenocarcinoma.
  • : 7522 Background: Lung adenocarcinoma (ADC) is a distinct biologic entity with unique gene amplifications (Weir B, Nature 2008).
  • Yet, comprehensive transcriptomic analysis, including microRNAs, specific to lung ADC are lacking.
  • METHODS: Using mRNA expression data from a discovery cohort of 154 patients with histologically proven early stage (I and II) lung ADC, signatures of oncogenic pathway and tumor microenvironment status were applied and further organized by hierarchical clustering to develop a metagene model.
  • Further, using in vitro assays in a large cohort of lung ADC cell lines (n = 42) with corresponding mRNA and microRNA data, novel microRNAs associated with a poor prognosis and their relationship to cisplatin resistance was elucidated.
  • RESULTS: In the discovery cohort of 154 patients with early stage disease, activation of oncogenic pathways associated with wound healing (angiogenesis), chromosomal instability, and STAT signaling were associated with an increased risk of recurrence (p<0.001).
  • Utilizing the extremes of survival to identify cohorts of patients as high and low risk phenotypes, using bayesian regression, a 100 gene signature ('metagene') that captured the diversity of signaling pathways unique to patients at increased risk of recurrence was identified and validated in an independent cohort (n = 364) of lung ADC samples with 78.3% accuracy.
  • Using in vitro cell proliferation assays, predicted high risk lung ADC cell lines were identified as being more resistant to cisplatin therapy than those predicted to be low risk (p=0.001).
  • CONCLUSIONS: mRNA and microRNA profiles reflect unique aspects of individual tumors and may characterize histology-specific tumor heterogeneity in lung ADC, providing an opportunity to better characterize the oncogenic process and refine therapeutic options.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963289.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Toyooka S, Hotta K, Nakamura H, Nakata M, Tada H, Yamashita M, Watanabe N, Sakamoto J, Aoe M, Date H: A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses. J Clin Oncol; 2009 May 20;27(15_suppl):7560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses.
  • The present phase III study assessed the efficacy and safety of carboplatin/paclitaxel and oral uracil-tegafur as the first study to compare intravenous and oral drugs in resected stage IB-IIIA NSCLC.
  • METHODS: The patients with pathological stage IB-IIIA NSCLC who underwent complete resection were randomized 1:1 to carboplatin (AUC 5) /paclitaxel (175 mg/m<sup>2</sup>) every 3 week for 4 cycles (A arm) or uracil-tegafur (250 mg/m<sup>2</sup>) daily for 2 years (B arm).
  • Randomization was stratified by histology and tumor stage.
  • Sixty patients had adenocarcinoma, 30 had squamous cell carcinoma, and 10 had other histologies.
  • Disease stage was IB in 53, IIA in 14, IIB in 19, and IIIA in 14 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963337.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16119 Background: Id1, involved in cell differentiation, proliferation, tumor angiogenesis and metastasis, has recently showed to mediate lung MTS from breast cancer (PNAS 2007).
  • 2009) and other non-adenocarcinoma tumors.
  • Most pts had PP advanced (22,7 % stage III; 68,2% stage IV) BCa.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Meng X Jr, Yu JM, Yang GR, Zhao SQ, Sun XD: &lt;sup&gt;11&lt;/sup&gt;C-PD153035 PET/CT molecular imaging of EGFR for evaluation of advanced non-small cell lung cancer (NSCLC) to EGFR-targeted therapy. J Clin Oncol; 2009 May 20;27(15_suppl):7576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] <sup>11</sup>C-PD153035 PET/CT molecular imaging of EGFR for evaluation of advanced non-small cell lung cancer (NSCLC) to EGFR-targeted therapy.
  • We report a pilot study evaluating the efficacy of <sup>11</sup>C-PD153035 PET/CT imaging as a "molecular fingerprint" to the EGFR-TKI in advanced NSCLC (stage IIIB/IV).
  • RESULTS: 12 patients (5 men, 7 women; age range, 60-79 years) have been enrolled in this study from August 2008, including 3 cases of squamous cell carcinoma, 1 case of large cell carcinoma, and the other of adenocarcinoma.
  • Tumor/lung ratio at 20 min was 4.14 ± 1.80.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963384.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Saji H, Tsuboi M, Miyajima K, Shimada Y, Ohira T, Ikeda N: Impact of number of resected and involved lymph nodes (LN) at the time of surgical resection on the survival of non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of number of resected and involved lymph nodes (LN) at the time of surgical resection on the survival of non-small cell lung cancer (NSCLC).
  • In this study we retrospectively evaluated the prognostic impact of the number of resected and involved lymph-nodes on the survival of stage I-III NSCLC.
  • RESULTS: Demographics are as follows: median age: 65.0 (22-87yrs), sex: 547 males and 381 females, median follow-up time: 2.5 yrs, clinical stage: 765 stage I, 84 stage II and 76 stage III, histology: 684 adenocarcinoma, 182 squamous cell carcinoma, and 62 others, operation: 870 lobectomy, 42 bilobectomy and 16 pneumonectomy, mean number of resected LN: 15 (1-49), mean number of involved LN: 0.9 (0-22).
  • Although a significant increasing in OS of 0-9 of number of resected LN cases compared with 10 and more was observed in all stages (P=0.024), no significant differentiation was observed in clinical stage I cases.
  • However, there is no significant different in stage I pts, which implies that selected LN sampling is enough in clinical stage I cases.
  • Further study such as LN dissection vs LN sampling in clinical stage I will be needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Xu Y, Zhou Y, Huang M, Zou B, Zhang X, Zhang X, Zhou L, Zhu J, Gong Y, Hou M, Lu Y: Gefitinib versus platinum contained doublet chemotherapy in chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer of adenocarcinoma histology: A retrospective case control study. J Clin Oncol; 2009 May 20;27(15_suppl):e19070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib versus platinum contained doublet chemotherapy in chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer of adenocarcinoma histology: A retrospective case control study.
  • : e19070 Background: The results of the ISEL study in non-small cell lung cancer (NSCLC) suggest greater benefit of gefitinib among Asian patients and non-smokers compared with the overall trial population.
  • METHODS: We conducted a retrospective case-control study to compare outcomes for gefitinib versus platinum doublet chemotherapy as first line treatment in selected NSCLC patients (stage IIIB/IV adenocarcinoma, PS 0-2).
  • Patient receiving platinum chemotherapy were selected on the basis of disease stage (IIIB or IV), gender, smoking history, WHO performance status (PS) (0-1, or 2) and age (< 60ys or ≥ 60ys) being matched to patients receiving gefitinib.
  • RESULTS: 99 chemo-naïve adenocarcinoma patients treated in our institute from January 2006 to December 2007 were collected: 33 received gefitinib and 66 received chemotherapy.
  • Gefitinib as first-line treatment confers clinically relevant benefit in Asian NSCLC patients with adenocarcinoma histology versus platinum based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962215.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Gibbons DL, Lin W, Creighton C, Zhang S, Lozano G, Kurie J: Use of a murine model of NSCLC to evaluate the role of the microRNA-200 family in regulating EMT and metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):11006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11006 Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide, primarily due to metastatic disease.
  • Unfortunately, we lack a clear understanding of the molecular and cellular basis for lung cancer metastasis, partly because the experimental study is hampered by lack of good models.
  • METHODS/RESULTS: To address this deficiency we have developed an experimental murine model of metastatic NSCLC using cell lines derived from a genetic mouse model of human lung adenocarcinoma that develops metastatic disease owing to the expression of K-ras<sup>G12D</sup> and p53<sup>R172H</sup>.
  • An expression signature derived from the spontaneous metastatic tumors in these animals is prognostic when applied to a large series of early-stage patient tumors, illustrating that the model recapitulates features of the human disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964037.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Zhou C, Zhou S, Zhang L: RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced NSCLC patients treated with cisplatin-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):8097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Stage IIIb/IV NSCLC patients were given cisplatin-based chemotherapy based upon expression levels of RRM1 and BRCA1 mRNA in the tumor.
  • RESULTS: 90 chemonaive, stage IIIB/IV, PS 0-1 NSCLC patients were enrolled.
  • Age 60 (40-78) yrs old, male/female: 73/27%; adenocarcinoma/squamous/adeno-squamous/undefined NSCLC: 49/33/11/7%;,stage IIIb/IV: 13/87%.
  • CONCLUSIONS: RRM1 and BRCA1 mRNA expression levels in non-small cell lung cancer are associated with clinical outcome to cisplatin-based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Morgensztern D, Waqar SN, Gao F, Govindan R: Improving survival for metastatic non-small cell lung cancer: A SEER database analysis from 1990 to 2005. J Clin Oncol; 2009 May 20;27(15_suppl):8078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving survival for metastatic non-small cell lung cancer: A SEER database analysis from 1990 to 2005.
  • : 8078 Background: Treatment of metastatic non-small cell lung cancer (NSCLC) has evolved over the last decade with the increased use of third-generation chemotherapy agents, established benefits from second-line chemotherapy, and the development of targeted agents.
  • METHODS: The Surveillance Epidemiology and End Results (SEER) registry was queried for patients with NSCLC stage IV, aged 21 or older, and diagnosed between 1990 and 2005.
  • Median age at presentation was 67 and most patients were male (58%), white (81%), and had adenocarcinoma (39%).
  • After adjusting for demographic factors, there were no significant differences in OS between adenocarcinoma and squamous cell from P1 to P3 (1990-2001).
  • However, P4 showed a significant increase in OS for adenocarcinoma compared with squamous cell (p = 0.02).
  • CONCLUSIONS: There has been a significant improvement in OS for stage IV NSCLC over the last 8 years.
  • The recent differences in outcomes based on histology observed in P4 may reflect the increased activity of newer therapies in adenocarcinoma compared with squamous cell, including gefitinib and erlotinib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962652.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis (LMC).
  • Of the initial endoscopic finding available 45 patients, Bormann type III and IV were 23 (51%) and 15 (33%) patients, respectively.
  • Clinically, initial advanced stage was predictive value of poor prognosis (P=0.009).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Shenglin M, Yaping X, Xinmin Y, Yang Y: Multidisciplinary management of brain metastases from non-small cell lung cancer: A retrospective study of 251 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary management of brain metastases from non-small cell lung cancer: A retrospective study of 251 patients.
  • : e19030 Background: The detection of brain metastasis(BM) is becoming increasingly common in patients with non-small cell lung cancer (NSCLC).
  • Variables analyzed included the recursive partitioning analysis (RPA) grouping, weight loss, LDH in blood serum, sex, age, time of brain metastasis (synchronous vs. metachronous), number of brain metastases, maximum diameter of largest brain lesion, Karnofsky performance status, histologic type (adenocarcinoma vs. other types of NSCLC), TNM stage (without consideration of brain involvement), and the treatment modality used for both the primary NSCLC tumor and brain metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Ohe Y, Ichinose Y, Nishiwaki Y, Yamamoto N, Negoro S, Duffield E, Jiang H, Saijo N, Mok T, Fukuoka M: Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. J Clin Oncol; 2009 May 20;27(15_suppl):8044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan.
  • METHODS: From Mar 06 to Oct 07, chemonaïve, never/light ex-smokers with stage IIIB/IV NSCLC and adenocarcinoma histology were randomized to G 250 mg/day (n=114) or C (AUC 5 or 6)/P (200 mg/m<sup>2</sup>) (n=119).
  • G demonstrated improved PFS and ORR, similar OS, higher QoL (TOI) and similar symptom improvement rates, and a more favorable tolerability profile compared with C/P in chemonaïve, never/light ex-smokers with advanced NSCLC and adenocarcinoma histology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Fan M, Xie L, Xu X, Zhang G, Chen J, Fu X, Zhou X, Li W, Jiang G: Phase I dose-escalation study of thoracic radiotherapy in combination with gefitinib in patients with IIIB/IV non-small cell lung cancer (NCT00497250). J Clin Oncol; 2009 May 20;27(15_suppl):e14581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-escalation study of thoracic radiotherapy in combination with gefitinib in patients with IIIB/IV non-small cell lung cancer (NCT00497250).
  • However, a higher incidence of interstitial lung disease, sometimes lethal, is also found.
  • METHODS: Patients with stage IIIB or selected stage IV, failure of platinum-based chemotherapy regimen NSCLC were eligible.
  • RESULTS: Since June 2007, 2 cohorts, a total of 16 patients, were enrolled and treated: 8 stage IIIB and 8 stage IV; 2 squamous-cell carcinoma and 14 adenocarcinoma; 8 smokers and 8 nonsmokers.
  • CONCLUSIONS: Thoracic radiotherapy up to 56 Gy concurrent with gefitinib 250 mg daily was well tolerated and clinically active in this group of pretreated Chinese NSCLC patients, including nonsmokers with adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963755.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Oizumi S, Akie K, Ogura S, Shinagawa N, Fukumoto S, Harada M, Kojima T, Kinoshita I, Dosaka-Akita H, Isobe H, Nishimura M: Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group 0601. J Clin Oncol; 2009 May 20;27(15_suppl):e19012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group 0601.
  • : e19012 Background: Platinum-containing therapy is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC).
  • Median age was 64 years (range, 42-75); 29 patients (73%) had adenocarcinoma, and 8 patients (20%) had squamous cell carcinoma.
  • Majority of the patients (32 cases, 80%) had stage IV disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Kobayashi K, Inoue A, Maemondo M, Sugawara S, Isobe H, Oizumi S, Saijo Y, Gemma A, Morita S, Hagiwara K, Nukiwa T: First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol; 2009 May 20;27(15_suppl):8016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group.
  • : 8016 Background: Based on our promising results of phase II studies estimating gefitinib in NSCLC pts with sensitive EGFR mutations (JCO 2006, BJC 2006), this multicenter phase III trial compared progression free survival (PFS) of first line gefitinib versus first line chemotherapy in EGFR mutation positive pts with stage IIIB/IV NSCLC.
  • Pts having sensitive EGFR mutations, measurable site(s), ECOG PS 0-1, age of 20-75 years, and no prior chemotherapy were randomized (1:1 ratio; balanced for institution, sex, and stage) to receive Arm A: gefitinb (250 mg/ day) orally, or Arms B: CBDCA AUC 6 and TXL 200mg/m2 in 21-day cycles until disease progression.
  • Their characteristics were well balanced between arms: median age=65 years; 64% female; 77% Stage IV; 93% adenocarcinoma, 61% non-smoker.
  • Furthermore, there were no interstitial lung disease and no toxic deaths in both arms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962807.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA: A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):3001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • Preclinical studies revealed that activated NK cells massively infiltrate lung tissue and improve recipient survival, suggesting a potential role in lung cancer therapeutics.
  • Pts characteristics: M/F 12/4; histology: adenocarcinoma/squamous cell carcinoma 13/3; stage IIIb/IV 2/14; 1<sup>st</sup>/2<sup>nd</sup> line treatment 13/3; median age 64 years (range, 50-71).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Kim K, Lee J, Chang M, Uhm J, Yun JA, Yi S, Park Y, Ahn J, Park K, Ahn M: Primary chemotherapy, stereotactic radiosurgery, or whole brain radiotherapy in non-small cell lung cancer (NSCLC) patients with asymptomatic brain metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e19063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy, stereotactic radiosurgery, or whole brain radiotherapy in non-small cell lung cancer (NSCLC) patients with asymptomatic brain metastases.
  • : e19063 Background: Approximately 25 to 30% of patients with lung cancer develop brain metastases at some stage and 12∼18% at the time of initial presentation.
  • Whole brain radiotherapy (WBRT) has long been a mainstay of treatment of brain metastases.
  • Subset analysis of 110 adenocarcinoma patients showed that the median OS for patients treated with primary SRS was longer than those of primary WRBT (29.3m vs 17.7m p=0.01) or primary chemotherapy (29.3m vs 14.6m p=0.04).
  • CONCLUSIONS: These results suggest that for NSCLC patients with asymptomatic brain metastases at first diagnosis, SRS rather than primary chemotherapy or WBRT might be considered as initial treatment, especially for patients with adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Gagnon B, Roseman M, Kasymjanova G, MacDonald N, Kreisman H, Small D: Protective effect of metformin in lung cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e22063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protective effect of metformin in lung cancer patients.
  • We report on the survival of lung cancer patients concomitantly exposed to metformin in our community-based program.
  • The factors that were included in the model were age, gender, stage, histology and metformin use.
  • 523 (62%) of those patients were diagnosed with adenocarcinoma; 488 (57%) were stage IIIB with pleural effusion/IV.
  • The Cox regression analysis demonstrated that age, gender, stage and use of metformin were significant prognostic factors for survival.
  • CONCLUSIONS: Thus, the result obtained from our model suggests that use of metformin may be associated with better survival of lung cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963206.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Sugarbaker DJ, Tilleman TR, Swanson SJ, Jaklitsch MT, Mentzer SJ, Mujoomdar AA, Bueno R: The role of extrapleural pneumonectomy in the management of pleural cancers. J Clin Oncol; 2009 May 20;27(15_suppl):7577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 32 patients had mediastinoscopy negative T4 lung cancer, 11 had metastases to only one pleura from extrathoracic sites, 10 had unilateral lung sarcomas involving the pleural envelope, 8 had thymomas metastatic to a pleural space, 2 were preoperatively diagnosed as mesotheliomas but at final pathology were determined to be small cell lung cancer and sarcomatoid carcinoma, and 2 represented primary mucoepidermoid and neuroectodermal malignancies.
  • Twenty-eight patients had stage IIIB (T4-N0-1) lung adenocarcinoma representing the largest homogeneous group of patients by cell type and stage.
  • Median survival for stage IIIB NSCLC was 16.7 months.
  • Patients with stage IIIB (T4, N0-1) NSCLC confined to a single pleural cavity or patients with thymoma involving one pleura may benefit from multimodality treatment including EPP.
  • Absence of residual nodal disease at resection is positively correlated with survival in the stage IIIB NSCLC group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963385.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Wozniak AJ, Kalemkerian GP, Gadgeel SM, Schneider BJ, Valdivieso M, Venkatramanamoorthy R, Hackstock DM, Chen W, Heilbrun LK, Ruckdeschel JD: A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • Median age 57.5 yrs, males-55%, stage IV 90%, adenocarcinoma 75%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U: Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e19089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • METHODS: Chemotherapy-naïve p diagnosed with stage IIIB or IV non squamous NSCLC received cisplatin (80 mg/m2), vinorelbine (25 mg/m2 IV days 1 and 8) and B (15 mg/kg IV) on day 1 every 3 weeks for up to 6 cycles followed by B 15 mg/kg alone every 3 weeks until disease progression.
  • P characteristics were: male 66.7%; median age 57 years (range 41-74); ECOG PS 0/1 (%) 33.3/66.7; adenocarcinoma/other (%) 74.1/25.9; stage IIIB/IV (%) 25.9/74.1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962195.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Kenmotsu H, Goto K, Naito Y, Nishiwaki Y, Kubota K, Ohmatsu H, Niho S, Yoh K, Nagai K, Saijo N: Analysis of optimal timing of gefitinib in sensitive non-small cell lung cancer (NSCLC) patients: Should we use gefitinib as first-line chemotherapy? J Clin Oncol; 2009 May 20;27(15_suppl):8068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of optimal timing of gefitinib in sensitive non-small cell lung cancer (NSCLC) patients: Should we use gefitinib as first-line chemotherapy?
  • : 8068 Background: In gefitinib-sensitive NSCLC such as Asian origin, adenocarcinoma, and never/light smoker, the superiority of gefitinib relative to carboplatin/paclitaxel as first-line chemotherapy was recently demonstrated (IPASS).
  • Patient characteristics (first-line/second or more-line) were as follows: median age (range) 68 (44-82)/64 (33-82); female 84/67%; non-smoker 80/57%; PS0-1 84/74%; adenocarcinoma 93/97%; stage IV 43/54%; recurrence after surgical resection 45/26%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962655.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Pavlakis N, Hirsh V, Reck M, Wu Y, Dansin E: MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data for 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Edelman MJ, Belani CP, Socinski MA, Ansari R, Obasaju CK, Monberg MJ, Chen R, Treat J: Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC).
  • Analyses of pts with lung cancer from the 1970s and 1980s indicated that the incidence of BM at the time of diagnosis was approximately 10%.
  • METHODS: 1135 chemonaïve pts with stage IIIB or IV NSCLC were randomized to receive: G 1000 mg/m<sup>2</sup> d 1, 8 plus C AUC 5.5 d 1; or G 1000 mg/m<sup>2</sup> days 1 and 8 plus P 200 mg/m<sup>2</sup> d 1; or P 225 mg/m<sup>2</sup> plus C AUC 6.0 d 1.
  • Stratification was based on stage, baseline weight loss, and presence or absence of BM.
  • RESULTS: BM rates by subgroup were as follows (%): overall (17.1), nonsquamous (19.3), squamous (6.9), <70 y (21.3), ≥ 70 y (7.1), female (19.2), male (15.7), Caucasian (16.7), African American (18.8%), Hispanic (22.2), PS 0 (12.9), PS 1 (19.7), weight loss <5% (18.3), weight loss ≥ 5% (15.1), and stage IV (19.0).
  • 1) The higher incidence of BM (17.1%) observed in this trial may be related to the increasing incidence of adenocarcinoma, or to the increasing sensitivity of imaging modalities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962650.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Dragnev KH, Cyrus JC, Rigas JR, DiSalvo WM, Dmitrovsky E: Association between triglyceride (TG) levels, other clinical characteristics, and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bexarotene. J Clin Oncol; 2009 May 20;27(15_suppl):8101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between triglyceride (TG) levels, other clinical characteristics, and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bexarotene.
  • METHODS: E 150 mg and B 400 mg/m2 were administered daily orally to pts with stage IV NSCLC, mostly as third line or higher.
  • RESULTS: Sixty-one pts with stage IV NSCLC were enrolled, 54% women and 72% with adenocarcinoma, 15% never smokers, 20% current smokers, 15% had prior anti-EGFR therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Pennell NA, Videtic GM, Murthy S, Mason D, Rice TW, Mazzone P, Samsa J, Rich T, Shapiro M, Mekhail T: A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC).
  • : 7557 Background: Concurrent chemoradiotherapy (CRT) is standard treatment for stage III NSCLC, although the management of resectable patients (pts) remains controversial.
  • We report an open-label phase I/II trial of the epidermal growth factor receptor inhibitor E added to perioperative CRT for resectable stage III NSCLC pts, followed by maintenance (m) E.
  • METHODS: Eligible pts had stage IIIA/B NSCLC, PS 0-1, and were resectable as determined by a thoracic surgeon.
  • 25 pts were treated in the phase II component: median age 60, 92% stage IIIA, 64% female, 72% PS 0, 64% adenocarcinoma, and 16% never smokers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963345.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Gamaz MB, Bouzid K: Use of gemcitabine plus vinorelbine (GV) to treat advanced and metastatic non-small cell lung cancer (NSCLC) in second line after recurrent disease. J Clin Oncol; 2009 May 20;27(15_suppl):e19104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of gemcitabine plus vinorelbine (GV) to treat advanced and metastatic non-small cell lung cancer (NSCLC) in second line after recurrent disease.
  • METHODS: From January 2007 to October 2008, twenty three patients with NSCLC stage IIIB or IV who received platine salts + taxane in first line were treated in second line with (GV) gemcitabine (G) 1,250 mg/m<sup>2</sup> D1 and D8 + vinorelbine (V) 25 mg/m<sup>2</sup> D1 and D8 every three weeks.
  • Twelve (12) patients had IIIB stage and 11 patients had IV stage disease.
  • Squamous cell cancer was found in 12 patients, adenocarcinoma in 11 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963044.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Crino L, Mezger J, Griesinger F, Zhou C, Reck MM: MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Ou SI, Zell JA: Frequency of carcinoma not otherwise specified (NOS) as a histologic diagnosis among non-small cell lung cancer (NSCLC) cases between 1989 to 2006: An epidemiologic study from the California Cancer Registry. J Clin Oncol; 2009 May 20;27(15_suppl):e19049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of carcinoma not otherwise specified (NOS) as a histologic diagnosis among non-small cell lung cancer (NSCLC) cases between 1989 to 2006: An epidemiologic study from the California Cancer Registry.
  • The proportion of carcinoma NOS was highest among stage 4 disease and increased significantly from 1989 to 2006 among all patients, both males and females, all 4 major ethnicities (Caucasian, African-American, Hispanic, and Asian), all age- categories, and all AJCC stages.
  • Among stage 4 patients, carcinoma NOS patients derived less survival benefit from chemotherapy than adenocarcinoma patients during the most recent period of diagnosis and Cox proportional hazards analysis indicated carcinoma NOS (vs. adenocarcinoma; HR = 1.061, 95% CI: 1.040- 1.083) and cytologically-diagnosed NSCLC (vs. histologically-diagnosed NSCLC, HR = 1.043, 95% CI: 1.024-1.062) were independent unfavorable prognostic factors for OS.
  • This may be partially attributed to the increasing number of the very elderly patients and stage 4 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962101.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Karp DD, Novello S, Cardenal F, Haluska P, Blakely LJ, Garland L, Paz-Ares LG, Dolled-Filhart MP, Johnson ED, Gualberto A: Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):8072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer.
  • METHODS: Fifty-six pts with non-adenocarcinoma NSCLC were enrolled.
  • RESULTS: Pts were 72% male, 28% >70 years old and 91% stage IV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962646.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Walker M, Peltz G, Houts A, Pohl G, Schwartzberg L, Stepanski E, Marciniak M: Psychosocial impact of cancer-related symptoms among patients with lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychosocial impact of cancer-related symptoms among patients with lung cancer.
  • : 6621 Background: Patients with lung cancer may experience adverse physical symptoms due to cancer, cancer treatment, or comorbid medical conditions.
  • METHODS: We conducted a retrospective analysis of self reported symptom burden with the 38-item Patient Care Monitor survey (PCM), collected as part of routine clinical care in 1,384 lung cancer patients identified by ICD-9 codes at 8 community oncology practices in the US.
  • Stage of disease was 19% stage IV, 22% stage I-III, and 59% unspecified.
  • Histological type was 36% adenocarcinoma, 18% squamous cell, 37% unspecified, and 9% other.
  • CONCLUSIONS: Cancer related symptoms are associated with FI and with psychosocial outcomes in lung cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Cetin K, Ettinger DS, Hei Y, O'Malley CD: Prognostic factors by histologic subtype in stage IV non-small cell lung cancer (NSCLC): A population-based survival analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988-2003). J Clin Oncol; 2009 May 20;27(15_suppl):11053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors by histologic subtype in stage IV non-small cell lung cancer (NSCLC): A population-based survival analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988-2003).
  • : 11053 Background: Representing roughly 85% of all lung cancers, NSCLC is frequently diagnosed at an advanced stage and has a poor prognosis.
  • To better understand the prognostic importance of select patient and tumor characteristics in late-stage disease, we examined survival in patients diagnosed with stage IV NSCLC.
  • METHODS: Data from SEER were used to study 53,319 patients with stage IV NSCLC diagnosed between 1988 and 2003, with follow-up through 2005.
  • The distribution of cases according to time period of diagnosis and select patient and tumor characteristics was described for each histologic subtype (squamous; adenocarcinoma (bronchioloalveolar adenocarcinoma (BAC), non-BAC); large cell; and other/unknown).
  • CONCLUSIONS: Survival among stage IV NSCLC patients improved over the study period, which may reflect the use of third generation chemotherapy as well as better supportive care.
  • Nonetheless, lung cancer remains a deadly disease, and the prognostic effect of demographic factors varies with histologic subtype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963160.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Gamelin E, Mineur L, Chevelle C, Cailleux P, Martin L, Bastit L, Roullet B, Hasbini A, Savary J, Cellier P: Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study. J Clin Oncol; 2009 May 20;27(15_suppl):4104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study.
  • : 4104 Background: Neoadjuvant chemoradiotherapy (CRT) with tegafur-uracil (UFT) plus leucovorin (LV) has shown promising results in patients with rectal adenocarcinoma (RAC).
  • METHODS: One hundred seventy seven pts with RAC stage T3 (T4 if anal extension) N<2, M0 were randomized to either RT alone (RT) (1.8 Gy/d, 45 G total) 5 days/w for 5 weeks or combined to CT (CRT) with daily UFT 300 mg/m<sup>2</sup> plus leucovorin 75 mg for 5 weeks.
  • 172 pts underwent surgery (97.2%), 5 pts were not resected (4 liver and 1 lung metastases plus 1 CVA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Shabbir M, Daniels L, Shirai K, Cole S, Willey J, Iovino L, Labarre K, Green MR: Prescribing plans (PP) of American Oncologists for first-line therapy (Rx) for patients with stage III (wet)/IV non-small cell lung cancer (NSCLC) and PS 2: Overall selection and impact of gender and smoking status. J Clin Oncol; 2009 May 20;27(15_suppl):e19046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prescribing plans (PP) of American Oncologists for first-line therapy (Rx) for patients with stage III (wet)/IV non-small cell lung cancer (NSCLC) and PS 2: Overall selection and impact of gender and smoking status.
  • : e19046 Background: Selection of oral EGFR inhibitors or chemotherapy as 2<sup>nd</sup> line in patients with NSCLC may be influenced by patients' performance status (PS), smoking status, gender; tumor histology; tolerance/response to 1<sup>st</sup>-line Rx; and patient expectations/desires.
  • METHODS: Between February '07 and October '08, we used a core case scenario of stage IV mucin positive adenocarcinoma (Adeno ca) of lung in a 68-year-old former smoker (FS; stopped 6 years ago) with PS 2, to study patient related variations in PP of almost 800 American medical oncologists during 10 live research events [393 MDs/5 events during 2008].
  • Impact of gender or/and smoking history on 1<sup>st</sup>-line Rx selection was assessed.
  • For a female NS with Adeno ca /PS2, ≥2/3 of MDs plan erlotinib 1<sup>st</sup>-line.
  • In the absence of testing results for EGFR expression by IHC, EGFR gene copy number by FISH, EGFR gene mutation testing, or kras mutation testing, our data show a direct correlation of patient "phenotype" and PP for erlotinib as 1<sup>st</sup>-line Rx, a setting not specifically an approved indications for this agent.
  • The impact of recently reported progression free survival data from an Asian phase III trial (IPASS: gefitinib or chemotherapy or as 1<sup>st</sup>-line therapy in non or former light-smoking patients with lung adenoca) on future prescribing plans in this clinical setting will be of great interest.
  • CONCLUSIONS: By our observations, smoking status dominates over gender in PP of oncologists when treating wet IIIB/IV Adeno ca of lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962104.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Shih J, Yang C, Su W, Hsia T, Tsai C, Chen Y, Chang H, Terlizzi E, Shahidi M, Miller VA: A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). J Clin Oncol; 2009 May 20;27(15_suppl):8013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2).
  • METHODS: Objective response rate is the primary endpoint of this 2-stage trial.
  • Based on 16 or more unconfirmed PRs in an interim analysis of the first 40 2<sup>nd</sup> line patients (pts) completing 1 course (28 days), accrual will continue to a total of 120 1<sup>st</sup> and 2<sup>nd</sup> line pts (expected completion of accrual by May 2009.
  • Eligible pts have stage IIIB/IV lung adenocarcinoma, EGFR mutation in exons 18-21 (tested by direct sequencing), measurable disease, ECOG PS 0-2 and adequate end organ function.
  • The trial was moved to stage 2 after 21 of the first 38 treated pts had objective response at 28 days.
  • An international Phase III trial program investigating BIBW 2992 in NSCLC, LUX-Lung, is now recruiting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962806.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Sorensen J, Hansen O, Vilmar A, Frank H: Prospective randomized phase III trial of triplet chemotherapy with paclitaxel + gemcitabine + cisplatin compared to standard doublet chemotherapy with vinorelbine + cisplatin in advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):8034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized phase III trial of triplet chemotherapy with paclitaxel + gemcitabine + cisplatin compared to standard doublet chemotherapy with vinorelbine + cisplatin in advanced non-small cell lung cancer.
  • Overall, median age was 62 years (range 38-75 yrs), 58% were males, 11% had performance status 2, 62% stage IV disease, 46% adenocarcinoma, and 28% squamous cell carcinoma (SCC), equally distributed between the regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962834.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Ebi N, Semba H, Tokunaga S, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine S, Okamoto I, Nakanishi Y, Lung Oncology Group in Kyushu (LOGIK): Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e19059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis.
  • : e19059 Background: Lung cancer is a disease of the elderly with median age at diagnosis of 70 yrs.
  • Patient characteristics: male/female = 12/16, median age = 82 (range 80-90), ECOG PS 0/1/2=7/13/8, stage IB/IIIA/IV=1/3/24, and adenocarcinoma (Ad)/non-Ad= 22/6.
  • There were two pts with possible interstitial lung disease including one treatment-related death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962159.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Lerouge D, Gervais R, Dansin E, Dujon C, Chouaid C, Riviere A, Precheur-Agulhon B, Piolat V, Zalcman G, Lartigau E: A fractionated schedule of oral vinorelbine (NVBo) with cisplatin (CDDP) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC): Safety and efficacy results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):7539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fractionated schedule of oral vinorelbine (NVBo) with cisplatin (CDDP) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC): Safety and efficacy results of a phase II trial.
  • METHODS: Non operable stage IIIA-IIIB NSCLC patients (pts) received an induction CT of 2 cycles of NVBiv 25 mg/m<sup>2</sup> + CDDP 80 mg/m<sup>2</sup> on D1 and NVBo 60mg/m<sup>2</sup> on D8 every 3 weeks.
  • RESULTS: Between October 05 and May 08, 70 pts were enrolled (68 evaluable for the safety, 64 for response) : 28% stage IIIA, 72% IIIB; 44 % squamous, 30 % adenocarcinoma; 85% male; median age 61 years (range 41;73); median KPS 90%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K: Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC).
  • METHODS: Patients with completely resected stage IB-IIIB NSCLC were randomized to either carboplatin (AUC3) plus paclitaxel (90mg/m2) (arm A) or carboplatin (AUC3) plus gemcitabine (1000 mg/m2) (arm B), q2w for 8 cycles within 8 weeks after surgery.
  • The patients were stratified by gender, histology (adenoca vs. non-adenoca) and disease stage.
  • The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Villaflor VM, Kanteti R, Watson SM, Karrison T, Vokes EE, Salgia R: Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E). J Clin Oncol; 2009 May 20;27(15_suppl):e19006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E).
  • EGFR activating mutations correlate with adenocarcinoma histology, non-smoking history, female gender, and Asian ethnicity.
  • Hence we collected data specific to the AA pt as they tend to have worse outcomes stage for stage.
  • Histology included NSCLC not specified-14, squamous cell- 16, adenocarcinoma-11, large cell-1 and 2 not available.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962520.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Fukuoka M, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Watkins C, Duffield E, Armour A, Mok T: Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol; 2009 May 20;27(15_suppl):8006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS).
  • : 8006^ Background: IPASS demonstrated overall superiority of first-line G vs C/P for progression-free survival (PFS) in never/light ex-smokers with stage IIIB/IV adenocarcinoma NSCLC in Asia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962786.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Wu Y, Mok T, Chu D, Han B, Liu X, Zhang L, Zhou C, Rukazenkov Y, Duffield E, Fukuoka M: Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). J Clin Oncol; 2009 May 20;27(15_suppl):8041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS).
  • : 8041^ Background: The IRESSA Pan Asia Study (IPASS) demonstrated superiority of G vs C/P for progression-free survival (PFS) in 1,217 chemonaïve, never/light ex-smokers with WHO PS 0-2, adenocarcinoma histology and stage IIIB/IV NSCLC.
  • G demonstrated improved efficacy (PFS and ORR), similar OS, higher QoL and similar symptom improvement rates and more favorable tolerability profile compared with C/P in chemonaïve, never/light ex-smokers with advanced NSCLC and adenocarcinoma histology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, Álvarez de Mon M, Sánchez-Hernández A, Gallego R, Torrego J: Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC).
  • This is a single-arm, open- labeled, single-stage phase II trial of cisplatin (C), docetaxel (D) and B for NSCLC.
  • METHODS: Eligibility criteria: chemo- naïve, stage IIIB wet or IV, non-squamous NSCLC, PS 0-1, no brain metastases and no history of gross hemoptysis.
  • RESULTS: 50 p were enrolled (enrollment completed): 24% female, median age 60 (36-74), PS 1: 64%, adenocarcinoma: 72%; stage IV: 92%.
  • CONCLUSIONS: Treatment with C, D and B, followed by maintenance B in 1<sup>st</sup> line of advanced non-squamous NSCLC shows an acceptable toxicity profile and promising efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Casal J, Vázquez S, León L, Lázaro M, Fírvida JL, Amenedo M, Alonso G, Santomé L, Afonso FJ: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • : 7537 Background: Combination of platinum-based chemotherapy and radiotherapy is the standard treatment for p with unresectable stage III NSCLC, but considering the high rates of recurrence, it is necessary to improve these results.
  • In this study, we aim to evaluate the role of erlotinib as maintenance therapy after a standard concurrent chemo-radiotherapy regimen in p with stage III NSCLC.
  • METHODS: P with unresectable stage IIIA/IIIB-without malignant effusions-NSCLC who had received a standard concurrent chemo-radiotherapy regimen and had no evidence of tumor progression were enrolled in this single arm, open-label phase II study and received erlotinib 150 mg/day po for 6 months.
  • Baseline characteristics: median age 62 years (range 41-76); male 94.6%; caucasian 100%; smokers/never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8.
  • CONCLUSIONS: Erlotinib as maintenance therapy is an active and well tolerated treatment after concurrent chemo- radiotherapy in p with stage III NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Belvedere O, Follador A, Rossetto C, Sibau AM, Defferrari C, Aita M, Meduri S, Fasola G, Ceschia T, Grossi F: Final report of a randomized phase II study of docetaxel/oxaliplatin (DO) and docetaxel (D) in previously treated non-small cell lung cancer (NSCLC) patients (pts). A novel design, Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 019). J Clin Oncol; 2009 May 20;27(15_suppl):e19010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final report of a randomized phase II study of docetaxel/oxaliplatin (DO) and docetaxel (D) in previously treated non-small cell lung cancer (NSCLC) patients (pts). A novel design, Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 019).
  • This one-stage, three-outcome phase II trial design (Sargent, Control Clin Trials 2001) had 21 evaluable pts/arm.
  • Pts characteristics: M/F, 76/24%; median age 62 yrs (range 43-69); ECOG PS 0/1, 36/64%; adenocarcinoma/other, 36/64%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962629.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Virani S, Almubarak M, Marano G, Rogers JS: Role of PET/CT scanning in detecting asymptomatic brain metastases in non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e19038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of PET/CT scanning in detecting asymptomatic brain metastases in non-small cell lung cancer.
  • : e19038 Background: Up to one-third of non-small cell lung cancer (NSCLC) patients are diagnosed with brain metastasis.
  • METHODS: We performed a retrospective chart review of 282 consecutive non-small cell lung cancer patients between February of 2005 and June of 2008.
  • For patients who had a PET/CT scan, the histological types were: adenocarcinoma (58.4%), unclassified (22.6%), squamous (13.2%), large cell (3.8%) and other (1.8%).
  • 19/53 patients were found to have asymptomatic brain metastasis on PET/CT scan (2 stage I, 1 stage II, 2 stage III and 13 stage IV).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962123.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Chang VT, Hoover DR, Cogswell J, Cholankeril M, Badin S, Yang W, Yan H, Gonzalez ML, Einhorn J, Kasimis BS: Comorbidity and survival in advanced non-small cell lung cancer (NSCLC) veteran patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20675

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity and survival in advanced non-small cell lung cancer (NSCLC) veteran patients.
  • We studied whether the Charlson Comorbidity Index (CMI), Cumulative Illness Rating Scale (CIRS), Kaplan Feinstein Index (KFI), and/or VA Comorbidity Scale (VA) independently predicted survival for NSCLC patients Methods: In an IRB approved protocol, the charts of 101 patients with Stage IIIA, IIIB or IV Non small cell lung cancer seen from 2004 through 2006 at a VA medical center were reviewed of whom 94 have already died.
  • Comorbidity scores ECOG performance status (PS), stage, number of treatments, serum LDH, and albumin levels were obtained or coded from medical records.
  • RESULTS: Median (M) patient age was 69 years (range 51-88), the M ECOG PS was 1 (range 0-4); 13 (13%) had stage IIIA, 27 (26%) IIB and 62 (61%) IV.
  • Histologies were adenocarcinoma in 48 (48%) pts, squamous cell in 37 (37%) pts, and other 17 (15%) pts.
  • In univariate survival analyses, the stage (p<0.001), ECOG PS (p<0.001), albumin (p<0.003), and the CIRS 17 (p <0.052) were predictive of survival; when, however, bisected by median values, the VA scale (p<0.027), ECOG PS (p<0.052) and albumin (p<.0017) were significantly related to survival but age, LDH, CMI, KFI and subscales of the CIRS (CIRS 16, CIRS 17, CIRS18) were not related to survival.
  • In multivariate proportional hazards analyses that included stage and a comorbidity index, the CIRS16 (p<.032) was an independent predictor of survival; the combinations of stage (p<0.008), ECOG PS (p<.004), stage (p<.006) and albumin (p<.002) were independent predictors of survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961684.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Laskin JJ, Pugh T, Jackson C, Sutcliffe M, Ionescu D, Melosky B, Ho C, Sun S, Murray N, Marra M: Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):8102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer.
  • Eligibility criteria included: stage IIIB/IV NSCLC; no prior chemo; ECOG ≤2; at least 2 of the following 4 criteria: women, never-smokers, Southeast Asian origin, adenocarcinoma and/or BAC.
  • The discovery of novel mutations in multiple pts suggests patterns that may shed light on lung cancer specific behaviour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Scagliotti G, Monica V, Ceppi P, Righi L, Cambieri A, Volante M, Novello S, Cappelletto E, Papotti M: Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):7521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer.
  • : 7521 Background: In non-small cell lung cancer (NSCLC) baseline thymidilate synthase (TS) levels are higher in squamous cell carcinoma (SCC) compared to adenocarcinoma (AC) and randomized clinical trials have shown a selective benefit for patients with non-squamous histology treated with pemetrexed, a TS-inhibiting agent.
  • METHODS: TS expression at both mRNA (using tissue microdissection and qRT-PCR) and protein (through immunohistochemistry, IHC) levels was tested in 34 surgically resected LCC (stage I=20,II=6,IIIa=8) and compared with TS expression in surgical cases of SCC (n= 31) and AC (n=40).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963288.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Luttgen MS, Marrinucci D, Lazar D, Malchiodi M, Clark P, Huynh E, Bethel K, Bazhenova L, Nieva J, Kuhn P: Circulating tumor cells monitored over time in lung cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):11025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells monitored over time in lung cancer patients.
  • While many current techniques employ immunomagnetic-enrichment based protocols focused on the importance of a particular CTC number as the indicator of patient status or outcome, we employ a cytometric, enrichment free approach using an immunofluorescent protocol to monitor CTC counts in patients with non-small cell lung cancer (NSCLC) over the course of treatment.
  • METHODS: Eligible patients had progressive stage IV NSCLC.
  • The histological subtypes in the 42 cases for which the data was available included adenocarcinoma (22/42), squamous cell carcinoma (6/42), large cell undifferentiated carcinoma (3/42), and non-small cell lung carcinoma not further described, poorly differentiated, or with a mixed pattern (11/42).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963968.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Di Maio M, Camps C, Smit EF, Schuette W, Georgoulias V, Takeda K, Quoix E, Wachters FM, Gebbia V, Gridelli C: Prognostic factors in patients enrolled in clinical trials of second-line chemotherapy for advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 11 randomized trials. J Clin Oncol; 2009 May 20;27(15_suppl):8082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients enrolled in clinical trials of second-line chemotherapy for advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 11 randomized trials.
  • Of the other 9 trials (1239 pts), 1197 pts (97%) had complete information: 78%/22% males / females, 83%/17% younger / older than 70, 28%/59%/13% Performance Status (PS) 0 / 1 / 2, 18%/82% stage IIIB / IV, 32%/47%/21% squamous / adenocarcinoma / other histology.
  • 84% were pretreated with platin and 44% had obtained objective response (OR) to 1<sup>st</sup> line treatment.
  • At multivariate analysis, prognosis was significantly influenced by gender (worse in males vs females, Hazard Ratio [HR] 1.23 [95%CI 1.04-1.45], p=0.01), by PS (worse in PS1 vs PS0, HR 1.36 [1.16-1.59], p=0.0001 and in PS2 vs PS0, HR 3.01 [2.41-3.76], p<0.00001), by tumor histology (better in adenocarcinoma vs squamous, HR 0.85 [0.73-0.99], p=0.04 and worse in other histology vs squamous, HR 1.27 [1.05-1.52], p=0.01), by stage (worse in stage IV vs IIIB, HR 1.28 [1.07-1.53], p=0.007), by type of previous treatment (worse for pts pretreated with platin vs pts not pretreated with platin, HR 1.49 [1.14-1.93], p=0.003), and worse for pts not obtaining OR vs pts obtaining OR during 1<sup>st</sup> line (HR 1.25 [1.10-1.44], p=0.001).
  • CONCLUSIONS: In addition to patient-related (gender, PS) or tumor-related factors (histology, stage), prognosis of pts eligible for 2<sup>nd</sup> line treatment of aNSCLC is significantly conditioned by previous use of platin and response to 1<sup>st</sup> line treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962659.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T: Phase I study of concurrent high-dose three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of concurrent high-dose three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC).
  • : 7546 Background: The optimal dose of radiotherapy remains unclear in concurrent chemoradiotherapy for unresectable stage III NSCLC.
  • METHODS: Eligible patients (unresectable stage III NSCLC, age ≥ 20 years, PS 0-1, V<sub>20</sub> ≤ 30%) received cisplatin (80mg/m<sup>2</sup> day 1) and vinorelbine (20mg/m<sup>2</sup> days 1 and 8) repeated every 4 weeks for 3-4 cycles.
  • Of these, 23 (74%) had adenocarcinoma and 20 (65%) had stage IIIA disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Tanaka F, Yoneda K, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Kondo N, Hasegawa S, Fukuoka K, Nakano T: Circulating tumor cells (CTCs) and endothelial cells (CECs) in primary lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells (CTCs) and endothelial cells (CECs) in primary lung cancer.
  • : 11066 Background: Circulating tumor cell (CTC), a surrogate of distant metastasis, and circulating endothelia cell (CEC), a surrogate of angiogenesis, are potentially useful in the diagnosis of malignant tumors, but clinical significance of CTC/CEC in primary lung cancer (LC) remains unclear.
  • Among LC cases, the incidence of case with CTC-positive (CTC-count, 1 or more) was highest in small cell carcinoma cases (7/10, 70.0%), followed by squamous cell carcinoma (9/22, 40.9%) and adenocarcinoma (23/94, 24.5%) cases; the incidence of CTC-positive case was significantly higher in stage IV cases (68.6%; p<0.001), but it should be noted that CTC was positive in 17.4% of stage I cases and 15.4% of stage II cases.
  • The mean CEC number (/4.0mL) was significantly higher in LC cases than in NM cases (97.5 versus 52.5, respectively; p=0.023), Among LC cases, the mean CEC significantly increased along with tumor progression (mean CEC for stage I, II, III, and IV cases: 58.7, 57.9, 83.4, and 178.4, respectively; p=0.002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Fidler MJ, Seba A, Farlow EC, Basu S, Kaiser-Walters K, Steker D, Coon J 4th, Kim AW, Bonomi P, Faber LP: Tumor survivin expression in locally advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemoradiation followed by surgical resection. J Clin Oncol; 2009 May 20;27(15_suppl):7595

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor survivin expression in locally advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemoradiation followed by surgical resection.
  • : 7595 Background: Recently tumor molecular markers have shown promise as prognostic and predictive indicators for survival in early and advanced stage NSCLC patients (pts.) treated with chemotherapy.
  • METHODS: This is a retrospective study that included stage III NSCLC pts who had adequate pre-treatment tumor specimens and were treated with platinum based chemotherapy regimens and concurrent thoracic radiation (40 Gy).
  • RESULTS: Characteristics of 33 pts: 15 females; median age 61; 17 adenocarcinoma, 10 squamous(sq), 5 undifferentiated, 1 adeno-sq.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Yang C, Hirsh V, Cadranel J, Chen Y, Park K, Kim S, Chao T, Oberdick M, Shahidi M, Miller V: Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX- Lung1): A preliminary report. J Clin Oncol; 2009 May 20;27(15_suppl):8062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with advanced adenocarcinoma of the lung (Stage IIIB/IV; ECOG 0-2), who have failed one or two lines of CT (including platinum) and progressed following at least 12 weeks of E or G are randomized in a 2:1 ratio to receive BSC plus either oral BIBW 2992 50 mg qd or placebo until disease progression or unacceptable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962637.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Skrzypski MT, Szymanowska A, Jassem E, Rzepko R, Pawlowski R, Wyrwicz L, Goryca K, Marjanski T, Rzyman W, Jassem J: Prognostic value of microRNAs (miRNAs) profiling in early-stage squamous cell lung cancer (SqCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of microRNAs (miRNAs) profiling in early-stage squamous cell lung cancer (SqCLC).
  • Currently, apart from clinical stage at diagnosis, there are no reliable clinical factors to select high risk pts for adjuvant chemotherapy. miRNAs profiling is expected to indicate pts with aggressive disease and to provide prognostic information.
  • Confounding effect of NSCLC pathology heterogeneity justifies searching for prognostic miRNAs separately in SqCLC and adenocarcinoma.
  • METHODS: Fresh frozen tumor tissue was obtained from 30 SqCLC stage I-II pts during curative pulmonary resection.
  • CONCLUSIONS: Four miRNAs: 10b, 146b, 193a(5p) and 484 are potentially related to high metastatic propensity of early stage SqCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963407.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Sanchez A, Provencio M, Artal A, Constenla M, Garcia-Gomez R, Viñolas N, Domine M, Perez FJ, Gayo J: Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small cell lung cancer (NSCLC): Prospective analysis to improve the patient's convenience on day 8 NVBO administration. J Clin Oncol; 2009 May 20;27(15_suppl):e19096

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small cell lung cancer (NSCLC): Prospective analysis to improve the patient's convenience on day 8 NVBO administration.
  • : e19096 Background: Severe neutropenia observed during chemotherapy (CT) is a clinical finding leading to treatment modification and, sometimes, life-threatening events.
  • METHODS: Between October 2007 and September 2008, 31 chemo-naïve p with histologically confirmed stage IIIB/IV NSCLC were included.
  • Patient's characteristics were: Median age, 62 years (range 32-73); males, 93.5%; smokers, 38.7%; all PS 0-1; adenocarcinoma, 33.3% / squamous, 36.7%; stage IIIB, 14.8% / IV, 85.2%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962248.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Johnson ML, Rizvi NA, Ginsberg MS, Miller VA, Kris MG, Pao W, Riely GJ: A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations. J Clin Oncol; 2009 May 20;27(15_suppl):8012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations.
  • : 8012 Background: KRAS mutations are present in 30% of lung adenocarcinomas and are associated with primary resistance to erlotinib and gefitinib.
  • METHODS: Two cohorts of pts with stage IIIB/IV NSCLC were eligible.
  • The successful enrollment over 15 months of 29 pts with tumors with known KRAS mutations demonstrates that trials of a KRAS-specific genotype in lung cancer are feasible, and should be standard in future studies targeting the KRAS pathway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962781.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Govindan R, Bogart J, Wang X, Hodgson L, Kratzke R, Vokes EE, Cancer and Leukemia Group B: Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol; 2009 May 20;27(15_suppl):7505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407.
  • : 7505 Background: Cisplatin, etoposide and concurrent thoracic radiation has remained the standard treatment for locally advanced unresectable non small cell lung cancer (NSCLC) over the past two decades.
  • METHODS: Eligible patients with previously untreated stage III NSCLC received thoracic radiation (70 Gy) along with carboplatin (AUC 5) and pemetrexed 500 mg/m<sup>2</sup> on day 1 administered intravenously every 21 days for 4 cycles (arm A) or the same chemotherapy regimen with weekly cetuximab for 6 weeks concurrent with radiation (arm B).
  • The most common histological type was adenocarcinoma (46% in Arm A and 41% in Arm B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963475.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K: S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):8015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study.
  • METHODS: Eligibility: treatment-naïve advanced stage non-squamous cell NSCLC, no requirement for EGFR positivity, PS 0-1, no brain metastases or hemoptysis.
  • Pt characteristics: median age 64 years (42-78), Male/Female 52/52, PS 0/1 43/61, stage IIIB/IV 9/95, adenocarcinoma: 81, current/former smoker: 82.
  • There were 4 treatment-related deaths: lung hemorrhage (2), infection (1), unknown (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Sanmartin E, Jantus Lewintre E, Sirera R, Miñana M, Navarro A, Cabrera A, Blasco A, Pla A, Rosell R, Camps C: Soluble vascular endothelial growth factor receptor 2 (VEGFR2): New biomarker in advanced non-small cell lung cancer (NSCLC)? J Clin Oncol; 2009 May 20;27(15_suppl):e22108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble vascular endothelial growth factor receptor 2 (VEGFR2): New biomarker in advanced non-small cell lung cancer (NSCLC)?
  • METHODS: We studied 106 healthy controls (c) and 467 advanced NSCLC patients (p) (stage IIIB and IV) treated with cisplatin and docetaxel.
  • The histological subtypes were: 31.4% squamous, 49.8% adenocarcinoma, 15.3% large cell and undifferentiated and 3.5% other.
  • On the other hand, we found no statistical differences according to sex, histology, or stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963505.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Fabre E, Medioni J, Dosset M, Dosset M, Tartour E, Oudard S, Riquet M, Adotevi O: T-lymphocyte responses to the human telomerase reverse transcriptase (hTERT) in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):3061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lymphocyte responses to the human telomerase reverse transcriptase (hTERT) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • Pts were required to present stage III or IV tumor, without any immune deficiency or immunosuppressive drug.
  • Thereafter, we analyzed its link with age (< 60 vs. ≥ 60 yrs), ECOG performance status PS (0-1 vs. 2-3), tumoral stage (III vs. IV), histological subtype (adenocarcinoma vs. other), and smoking status (never smoker vs. smoker).
  • They presented a stage III (n = 6) or IV (n = 27) disease.
  • Eighteen pts presented anti-hTERT T lymphocytes (54%); among them we found 12 pts ≥ 60 yrs (70%), 14 adenocarcinoma (77%), 13 stage IV (72%), 7 pts with PS 2/3 (41%), and 13 smokers (72%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Bradbury PA, Twumasi-Ankrah P, Ding K, Leighl NB, Goss GD, Laurie S, Shepherd FA, Seymour L: The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC).
  • We evaluated the validity of this exclusion criterion, by investigating the OS of stage IV NSCLC pts with (BMet) and without (non-BMet) a prior history of BMet recruited to NCIC CTG CTs.
  • RESULTS: Of 1,349 stage IV pts, 131 had a history of BMet.
  • Female gender (41% vs. 33%, p=0.04) and adenocarcinoma (66% vs. 51%, p=0.005) was more common in the BMet cohort.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962651.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Lind JS, Dingemans AC, Groen HJ, Smit EF: A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naive patients (≥ 18 years; performance status 0-1) with pathologically proven irresectable stage IIIB or IV NSCLC were eligible.
  • RESULTS: 50 pts were enrolled: 22 females; median age 60 yrs (range 41-78); 30 PS 0; 37 stage IV; 34 adenocarcinoma; 11 never smokers; 10/33 EGFR mutations (exons 19 (n=5), 20 (n=1), 21 (n=4)); 3/33 K-Ras mutations.
  • CONCLUSIONS: The combination of sorafenib and erlotinib is safe and has clinically significant anti-tumor activity in chemotherapy-naive patients with stage IIIB/IV NSCLC, with significant changes in CECs, VEGF, and metabolic tumor activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962809.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Tojo T, Tojo T, Naito H, Kimura M, Takasawa S, Dohi Y, Nagata Y, Taniguchi S: Regenerating gene 1α (REG 1α) expression and new treatment strategies in early non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22178

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regenerating gene 1α (REG 1α) expression and new treatment strategies in early non-small cell lung cancer.
  • In the present study, to elucidate roles for REG Iα in non-small cell lung cancer (NSCLC), we investigated REG Iα expression in NSCLCs, focusing especially on its relationship with prognosis.
  • METHODS: We enrolled 70 NSCLCs (adenocarcinoma (AC)(n=48) and squamous cell carcinoma (SCC)(n=22)) who received surgery at Nara Medical University Hospital.
  • Total RNA was extracted from each tumor tissue and corresponding normal lung tissue (NL)(n=70), cDNA was then reverse-transcribed from total RNA, and quantitative real-time reverse transcriptase-polymerase chain reaction was then carried out.
  • In case of stage I, none of REG 1α negative patient died in both ACs and SCCs compared with 4 patients died of positive patients (AC:2, SCC:2), and also the survival rate among the REG 1α positive patients was significantly worse than among the negative patients in ACs (P<0.01) and SCCs (P<0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963718.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Kubota K, Kunitoh H, Seto T, Shimada N, Tsuboi M, Okamoto H, Masuda N, Maruyama R, Shibuya M, Watanabe K: A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503. J Clin Oncol; 2009 May 20;27(15_suppl):7561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503.
  • : 7561 Background: Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC.
  • METHODS: Patients with completely resected stage IB, IIA, IIB or stage IIIA NSCLC were stratified by stage (IB/IIA vs. IIB/IIIA) and institution and randomized to receive 3 cycles of DOC (60 mg/m2, day 1) plus CIS (80 mg/m2, day 1) or 3 cycles of PAC (200 mg/m2, day 1) plus CAR (AUC 6, day 1).
  • Patients' demographics (DC/PA): median age 63/59 years, 60%/66% male, 17%/22% PS 1, 79%/73% adenocarcinoma, 40%/40% of patients were stage IB/IIA, 60%/60% IIB/IIIA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Thatcher N, Stroyakovskiy D, Zhou C, Bearz A, Isla D, Griesinger F, Pavlakis N: MO19390 (SAiL): Incidence of hemorrhage with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Incidence of hemorrhage with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • Baseline characteristics for pts were (%): male 60.1; Caucasian/Asian/other 80.1/15.6/4.3; stage IIIB/IV 19.5/80.5 (no data for 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; central tumor location yes/no (Y/N) 27.3/72.7; cavitated tumor Y/N 2.6/97.4; smoking history Y/N 70/30; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962523.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N: Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project. J Clin Oncol; 2009 May 20;27(15_suppl):1540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project.
  • : 1540 Background: We have investigated the individualized benefit of CT screening as Anti-Lung Cancer Association projects (presented at ASCO 2006-2008).
  • However, there has not been enough information about the relationship of lung cancer stage to tumor size in repeated CT screening.
  • Therefore, we evaluated the stage-size relationship of these asymptomatic lung cancer cases diagnosed by long-term repeated screening with low-dose helical CT.
  • Within categories of tumor size, the distribution of pathological stage, histology, lymph node status, and distant metastases was determined.
  • RESULTS: Pathological stage has a strong relationship to tumor size at baseline screening (spearman r = 0.63, p = 0.013) and repeated screening (r = 0.65, p < 0.001).
  • Histology for the categories 15 mm or less was localized bronchioloalveolar carcinoma in 13 cases, adenocarcinoma with mixed subtype in 11 cases, invasive adenocarcinoma in five cases, other non-small cell carcinoma in 10 cases, and small cell carcinoma in one case.
  • In multivariate analyses, pathological stage was related to only tumor size (standardized regression coefficient beta = 0.59, p < 0.001) whereas histology was related to tumor size (beta = 0.43, p < 0.001) and smoking index (beta = 0.28, p = 0.016).
  • CONCLUSIONS: These results provide direct evidence of a stage-size relationship in long-term repeated CT screening for lung cancer.
  • Furthermore, early detection of lung cancer of 15 mm or less in diameter leads to the detection of early-stage (N0M0) lung cancer in repeated CT screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Yumuk PF, Teomete M, Dane F, Cabuk D, Basaran G, Turhal NS: Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC).
  • We aimed to determine the effect of dose reductions of platinums on outcome of stage IIIB/IV NSCLC.
  • RESULTS: Median age was 60 years (range: 28-87), 79% of patients were male, 31% were 65 yearsold/older, 55% had PS of 0, and 27% had stage IIIB disease.
  • Histological subtypes were squamous cell in 32%, adenocarcinoma in 34%, and NSCLC in 31%.
  • Patients with PS of 0, no weight loss, stage IIIB disease, receiving combination CT with docetaxel-cisplatin, and having partial response to treatment lived significantly longer.
  • On multivariate analysis weight loss, stage and type of response to treatment had an impact on OS.
  • CONCLUSIONS: Using lower doses of platinum compounds in combination chemotherapy for stage IIIB/IV non-small cell lung cancer might not have a negative impact on survival and definitely have a better toxicity profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962161.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Pirker R, Rodrigues-Pereira J, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Emig M, Gatzemeier U: Prognostic factors in advanced NSCLC: Experience from the FLEX trial. J Clin Oncol; 2009 May 20;27(15_suppl):8083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patient baseline characteristics were: 70% male, median age 59 (18-83) years, 31% older than 65 years, 94% stage IV, 47% adenocarcinoma, 34% squamous cell carcinoma, 83% ECOG 0/1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962658.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Kawamura T, Nomura M, Tojo H, Fujii K, Hamasaki H, Mikami S, Bando Y, Kato H, Nishimura T: Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. J Proteomics; 2010 Apr 18;73(6):1089-99
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma.
  • We used formalin-fixed paraffin-embedded (FFPE) materials for biomarker discovery in cases of lung cancer using proteomic analysis.
  • We conducted a retrospective global proteomic study in order to characterize protein expression reflecting clinical stages of individual patients with stage I lung adenocarcinoma without lymph node involvement (n=7).
  • In addition, we studied more advanced stage IIIA with spread to lymph nodes (n=6), because the degree of lymph node involvement is the most important factor for staging.
  • More than 500 proteins were identified from IA and IIIA cases, and non-parametric statistics showed that 81 proteins correlated significantly with stage IA or IIIA.
  • [MeSH-major] Adenocarcinoma / metabolism. Computational Biology / methods. Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Paraffin / chemistry. Proteomics / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19948256.001).
  • [ISSN] 1876-7737
  • [Journal-full-title] Journal of proteomics
  • [ISO-abbreviation] J Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Proteome; 8002-74-2 / Paraffin
  •  go-up   go-down


90. Okamoto J, Onda M, Hirata T, Miyamoto S, Akaishi J, Mikami I, Hirai K, Haraguchi S, Koizumi K, Shimizu K: Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women. Gend Med; 2006 Sep;3(3):223-35
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women.
  • BACKGROUND: Although clinical differences in lung cancer between men and women have been noted, few studies have examined the sex dissimilarity using gene expression analysis.
  • OBJECTIVE: The purpose of this study was to determine the different molecular carcinogenic mechanisms involved in lung cancers in Japanese men and women.
  • METHODS: Patients who received surgery for stage I lung adenocarcinoma were included.
  • RESULTS: In a microarray analysis of tissue from 13 men and 6 women, 12 genes were under-expressed and 24 genes were overexpressed in lung adenocarcinoma in women compared with men.
  • CONCLUSION: Thirty-six genes that characterize lung adenocarcinoma by sex were selected.
  • This information may contribute to the development of novel diagnostic techniques and treatment modalities that consider sex differences in lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. RNA, Neoplasm / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081955.001).
  • [ISSN] 1550-8579
  • [Journal-full-title] Gender medicine
  • [ISO-abbreviation] Gend Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm
  •  go-up   go-down


91. Chen KY, Lee YC, Lai JM, Chang YL, Lee YC, Yu CJ, Huang CY, Yang PC: Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer. Eur J Cancer; 2007 Mar;43(4):782-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer.
  • To find novel prognostic factors, we used the expression profile of a poor prognostic factor of lung cancer, survivin (BIRC5), as a template to search for and compare transcriptome expression profiles in a lung adenocarcinoma microarray dataset.
  • The trophinin expression in lung cancer specimens was examined by immunohistochemical staining.
  • For stage I lung adenocarcinoma, the patients without trophinin expression had a better overall and disease-free survival.
  • Through a combination of data mining and biochemical assays, we identified trophinin, which could enhance cell invasion, as a novel prognostic factor for early stage lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Lung Neoplasms / diagnosis. Microtubule-Associated Proteins / metabolism. Neoplasm Invasiveness / diagnosis. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17254769.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / TRO protein, human
  •  go-up   go-down


92. Mino N, Miyahara R, Nakayama E, Takahashi T, Takahashi A, Iwakiri S, Sonobe M, Okubo K, Hirata T, Sehara A, Date H: A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. J Surg Oncol; 2009 Sep 1;100(3):267-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma.
  • We conducted a retrospective study to determine whether the expression of the membrane type of ADAM12 (ADAM12-L) could be a prognostic factor in resected pathological (p-) stage I lung adenocarcinoma.
  • METHODS: ADAM12-L mRNA expression was quantified by a reverse-transcription polymerase chain reaction in tissue samples from 84 completely resected p-stage I lung adenocarcinoma patients.
  • CONCLUSIONS: ADAM12-L mRNA expression is an independent prognostic factor in resected p-stage I lung adenocarcinoma, and is significantly correlated with tumor differentiation stage and postoperative cancer recurrence.
  • [MeSH-major] ADAM Proteins / genetics. Adenocarcinoma / mortality. Disintegrins / genetics. Lung Neoplasms / mortality. Membrane Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544357.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Disintegrins; 0 / Membrane Proteins; 0 / RNA, Messenger; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins
  •  go-up   go-down


93. Carvalho S, Branco R, Serralheiro P, Saraiva T, Carvalho L: [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University]. Rev Port Pneumol; 2006 May-Jun;12(3):255-68
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University].
  • [Transliterated title] Adenocarcinoma do pulmão: Aplicação da classificação WHO 1999/2004 à casuística do Serviço de Anatomia Patológica do Hospital da Universidade de Coimbra.
  • A study of 701 primary adenocarcinomas of the lung was made at the Department of Pathology of the Hospital da Universidade de Coimbra for a period of fifteen years, between 1990 and 2004.
  • The criteria defined by the WHO classification of Tumours of the Lung, Pleura, Thymus and Heart 2004 were applied to the primary adenocarcinomas of the lung and as was expected, bronchioloalveolar carcinomas had its incidence in women while acinar adenocarcinomas were diagnosed mainly in men.
  • These conclusions were obtained via surgical specimens and when surgical biopsies were representative and those were mainly in stage IIB and IIIA.
  • A number of 109 cases had the final diagnosis of adenocarcinoma of the lung based on morphology and immunohistochemistry criteria.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. International Classification of Diseases. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967175.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


94. Seki N, Takasu T, Sawada S, Nakata M, Nishimura R, Segawa Y, Shibakuki R, Hanafusa T, Eguchi K: Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer; 2010 Dec;70(3):329-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma.
  • METHODS: The expression of eIF4E and 4E-BP1 was semiquantitatively examined with immunohistochemical staining in 80 patients with pathological stage I invasive lung adenocarcinoma.
  • Unfavorable prognostic factors for survival were age greater than 65 years (P=0.015), pathological stage IB disease (P=0.045), high eIF4E expression (P=0.008), and low 4E-BP1 expression (P=0.007).
  • CONCLUSIONS: Both eIF4E and 4E-BP1 are potential new prognostic factors for survival and stratification in patients with pathological stage I lung adenocarcinoma.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Eukaryotic Initiation Factor-4E / metabolism. Lung Neoplasms / diagnosis. Phosphoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20621385.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / EIF4EBP1 protein, human; 0 / Eukaryotic Initiation Factor-4E; 0 / Phosphoproteins
  •  go-up   go-down


95. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC: Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst; 2007 Aug 15;99(16):1257-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
  • We examined whether the cytokine gene expression profile of noncancerous lung tissue could predict the metastatic capability of adjacent lung adenocarcinoma.
  • METHODS: We analyzed a 15-cytokine gene expression profile in noncancerous lung tissue and corresponding lung tumor tissue from 80 US lung adenocarcinoma patients using real-time quantitative reverse transcription-polymerase chain reaction.
  • We then used unsupervised hierarchical clustering and Prediction Analysis of Microarray classification to test the prognostic ability of the 15-cytokine gene profile in the US patients and in an independent validation set comprising 50 Japanese patients with stage I disease.
  • RESULTS: A 15-cytokine gene signature in noncancerous lung tissue primarily reflected the lymph node status of 80 lung adenocarcinoma patients, whereas the gene signature of the corresponding lung tumor tissue was associated with prognosis independent of lymph node status.
  • Cytokine Lung Adenocarcinoma Survival Signature of 11 genes (CLASS-11), a refined 11-gene signature, accurately classified patients, including those with stage I disease, according to risk of death from adenocarcinoma.
  • CLASS-11 prognostic classification was statistically significantly associated with survival and was an independent prognostic factor for stage I patients (hazard ratio for death in the high-risk CLASS-11 group compared with the low-risk CLASS-11 reference group = 7.46, 95% confidence interval = 2.14 to 26.05; P = .002).
  • CONCLUSION: CLASS-11, which consists of genes for pro- and anti-inflammatory cytokines, identifies stage I lung adenocarcinoma patients who have a poor prognosis.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / mortality. Cytokines / genetics. Gene Expression Profiling. Lung Neoplasms / classification. Lung Neoplasms / mortality
  • [MeSH-minor] Female. Humans. Lung / metabolism. Lung / pathology. Lymph Nodes / pathology. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686824.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


96. Seki N, Sawada S, Nakata M, Inoue T, Nishimura R, Segawa Y, Shibakuki R, Eguchi K: Lung cancer with localized ground-glass attenuation represents early-stage adenocarcinoma in nonsmokers. J Thorac Oncol; 2008 May;3(5):483-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer with localized ground-glass attenuation represents early-stage adenocarcinoma in nonsmokers.
  • BACKGROUND: Studies of lung cancer showing localized ground-glass attenuation (GGA) on thin-section computed tomography (TSCT) have been limited to resected stage IA adenocarcinomas.
  • This study aimed to clarify the features of localized GGA cancer as a distinct clinicoradiological entity through a survey of lung cancers of all types.
  • METHODS: From 2000 through 2002, 492 patients with newly diagnosed stage I-IV lung cancer underwent TSCT at a single institution.
  • Survival rates were higher in patients with a GGA ratio > or = 50% and stage IB lung cancer than in patients with a GGA ratio < 50% and stage IA lung cancer.
  • CONCLUSION: Localized GGA cancer, with presurgical prognostic factors of tumor size and GGA ratio, represents early-stage lung adenocarcinoma in nonsmokers.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449000.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. González-Aragoneses F, Moreno-Mata N, Cebollero-Presmanes M, García-Yuste M, Cañizares-Carretero MA, Molins-López-Rodó L, Quevedo-Losada S, Torres-Lanzas J, Alvarez-Fernández E, Spanish Multicenter Study of Neuroendocrine Tumours of the Lung of the Spanish Society of Pneumonology, ThoracicSurgery (EMETNE-SEPAR): Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. Cancer; 2007 Oct 15;110(8):1776-81
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung.
  • BACKGROUND: The prognostic significance of the presence of a neuroendocrine marker (synaptophysin, SY) was analyzed in stage I of squamous carcinoma and adenocarcinoma of the lung.
  • METHODS: A multicentric retrospective study was conducted with immunohistochemical staining in a single center of 318 patients resected for squamous carcinoma or adenocarcinoma in pathologic stage I.
  • RESULTS: In all, 162 cases of squamous carcinoma and 156 cases of adenocarcinoma were identified, which included 105 patients in stage IA (50 patients with squamous carcinoma and 55 patients with adenocarcinoma) and 213 in stage IB (112 with squamous carcinoma and 101 with adenocarcinoma).
  • CONCLUSIONS: Stage I of squamous carcinoma and adenocarcinoma of the lung with SY+ has a poor prognosis, with a higher frequency of recurrence and lower survival rates.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Neoplasm Recurrence, Local / metabolism. Synaptophysin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724707.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Synaptophysin
  •  go-up   go-down


98. Haraguchi N, Satoh H, Kikuchi N, Kagohashi K, Ishikawa H, Ohtsuka M: Prognostic value of tumor disappearance rate on computed tomography in advanced-stage lung adenocarcinoma. Clin Lung Cancer; 2007 Mar;8(5):327-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of tumor disappearance rate on computed tomography in advanced-stage lung adenocarcinoma.
  • BACKGROUND: The proportion of tumor disappearance rate (TDR) on conventional computed tomography (CT) is associated with less aggressive biology, and patients with small peripheral adenocarcinoma accompanied by the TDR component showed better prognosis.
  • These findings led us to the idea that even advanced-stage adenocarcinomas with a higher TDR in the primary lesion on CT might suggest slowly progressing cancer.
  • This study was designed to determine the value of the TDR area in the primary site of advanced-stage lung adenocarcinoma with CT and correlate the CT findings with clinical outcome.
  • PATIENTS AND METHODS: In 103 patients with stage IIIB and IV lung adenocarcinoma, CT appearances and clinical data were reviewed retrospectively.
  • Three methods were used in the evaluation of the TDR area: method I, consolidation on mediastinal windows/mass on lung windows > 75% or not; method II, maximum diameter on mediastinal windows/maximum diameter on lung windows (diameter ratio) > 75% or not; and method III, TDR area on lung windows > 25% or not.
  • RESULTS: In univariate analysis, patients with lung adenocarcinoma with TDR have a more favorable prognosis than those without TDR in all 3 methods (method I, P = 0.001; method II, P = 0.024; method III, P = 0.014; log-rank test).
  • In multivariate analysis, a favorable prognosis in patients with adenocarcinoma with TDR was shown in method I (P = 0.015) and method III (P = 0.006).
  • CONCLUSION: As shown in patients with small peripheral lung adenocarcinoma, those with TDR on CT tended to have a good prognosis in contrast to those without TDR, even in patients with advanced-stage lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / radiography. Lung Neoplasms / mortality. Lung Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562232.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Niki Y, Oka M: Synchronus presentation of early-stage small cell carcinoma and adenocarcinoma in the same lung lobe. Intern Med; 2006;45(5):287-91
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronus presentation of early-stage small cell carcinoma and adenocarcinoma in the same lung lobe.
  • A 73-year-old man with no symptoms was admitted to our hospital with a nodular shadow (>2 cm) in the left upper lung field on chest X-ray.
  • A histological diagnosis (small cell carcinoma) was obtained by bronchoscopic examination including a transbronchial lung biopsy (TBLB).
  • While the nodule in the left S(1+2) (small cell carcinoma) had become completely necrotic by the time the final diagnosis was made after resection of the left upper lobe, histological diagnosis of the nodule in the left S3 revealed a well differentiated adenocarcinoma.
  • Synchronous presentation of early-stage lung cancer consisting of small cell carcinoma and adenocarcinoma was identified in the same left upper division of the lung.
  • Because there have been the few previous reports regarding cases of synchronous presentation of early-stage lung cancer in the same lung lobe, we also report on the clinical characteristics, thus adding this case to the five previously reported cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Small Cell / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595996.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


100. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM: A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res; 2008 Sep 1;14(17):5565-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
  • PURPOSE: Clinical staging does not adequately risk stratify patients with early stage non-small cell lung cancer.
  • We sought to generate a real-time PCR (RT-PCR)-based prognostic model in patients with early stage lung adenocarcinoma, the dominant histology of lung cancer in the United States.
  • EXPERIMENTAL DESIGN: We studied gene expression of 61 candidate genes in 107 patients with completely surgically resected lung adenocarcinoma using RT-PCR.
  • Risk score predicted mortality better than clinical stage or tumor size (adjusted hazard ratio, 6.7; 95% confidence interval, 1.6-28.9; P=0.001).
  • Among 70 patients with stage I disease, 5-year overall survival was 87% among patients with low-risk scores, and 38% among patients with high-risk scores (P=0.0002).
  • CONCLUSIONS: This multigene assay predicts overall and disease-free survival significantly better than clinical stage and tumor size in patients with early stage lung adenocarcinoma and performs especially well in patients with stage I disease.
  • Prospective clinical trials are needed to determine whether high-risk patients with stage I disease benefit from adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18765549.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down






Advertisement